Skip to main content

Table 1 Demographic characteristics, clinical manifestations, immunological features, and treatment of patients with SSc

From: Systemic sclerosis and pregnancy outcomes: a retrospective study from a single center

Disease subtype (n of patients)

Diffuse SSc (n = 2)

Limited SSc (n = 9)

Sine SSc (n = 10)

Maternal age at delivery (y)

38.8 ± 1.15

34.3 ± 4.69

36.0 ± 3.23

Disease duration at conception (y)

12 ± 10.4

6.4 ± 5.2

4.45 ± 5.7

Cumulative clinical manifestations

 Raynaud’s phenomenon

2 (100)

9 (100)

10 (100)

 Digital ulcers

2 (100)

3 (33.3)

1 (10)

 Arthritis

1 (50)

2 (22.2)

0

 Telangiectasia

2 (100)

4 (44.4)

0

 Calcinosis

1 (50)

2 (22.2)

0

 Puffy fingers/sclerodactyly

2 (100)

6 (66.7)

0

 Esophageal dysmotility

2 (100)

4 (44.4)

3 (30)

 Interstitial lung disease

2 (100)

4 (44.4)

1 (10)

 FVC (%)

80 ± 21.7

84.6 ± 16.9

99.3 ± 8.4

 DLCO (%)

68.3 ± 21.3

69.6 ± 22

78.3 ± 11.9

 Pulmonary arterial hypertension

0

0

0

 Scleroderma renal crisis

0

0

0

Immunological features

 Antinuclear antibodies

2 (100)

9 (100)

10 (100)

 Anti-Scl70 antibody

1 (50)

2 (22.2)

1 (10)

 Anti-centromere antibody

0

2 (22.2)

6 (60)

 Anti-RNA polymerase antibody

1 (50)

2 (22.2)

1 (10)

 Anti-cardiolipin antibodies

0

0

0

 Anti-β2GPI antibodies

0

1 (11.1)

0

 Lupus anticoagulant

0

0

0

 Anti-Ro/SSA antibody

0

3 (33.3)

2 (0)

Treatment at conception

 Calcium channel blockers

0

4 (44.4)

3 (33.3)

 ERA

0

1 (11.1)

1 (10)

 PDA-5 inhibitors

0

0

0

 Proton pump inhibitors

1 (50)

1 (11.1)

2 (20)

 Corticosteroids

1 (50)

3 (33.3)

1 (10)

  1. Categorical variables are expressed as number (percentage) and continuous variables as mean ± standard deviation
  2. Abbreviations: SSc systemic sclerosis, y years, FVC forced vital capacity, DLCO diffuse lung capacity of carbon monoxide, β2GPI beta2-glicoprotein I, ERA endothelin receptor antagonist, PDA-5 phosphodiesterase type 5